Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones

January 22, 2024

https://www.globenewswire.com/news-release/2024/01/22/2812929/0/en/Alterity-Therapeutics-Issues-Shareholder-Letter-Highlighting-Pipeline-Advances-and-Key-Upcoming-Milestones.html

– Preliminary Data from ATH434-202 Study Expected in 1H 2024 –
– ATH434-201 Study to Complete in November 2024 –

MELBOURNE, Australia and SAN FRANCISCO, Jan. 22, 2024 (GLOBE NEWSWIRE) — Alterity Therapeutics (ASX:ATH, NASDAQ:ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today issued a letter to shareholders.

Read more at globenewswire.com

Related news for (ATHE)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.